retatrutide phase 2 results obesity nejm 2023 (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide Phase 2 NEJM Trial:

[DOI] [PMC free article] [PubMed] [Google Scholar] 186.Capuccio S., Scilletta S., La Rocca F., Miano N., Di Marco M., Bosco G., Barbagallo F.G., Scicali R., Piro S., Pino A

Retatrutide is a Phase 3 investigational compound not yet approved by any regulatory agency as of June 2026

Early shifts occur in 24 weeks , with full metabolic recalibration over 812 weeks depending on diet, stress, sleep, and microbiome diversity

After delivery, 3.5 hours after the latest dose of liraglutide, the concentration of liraglutide was measured in maternal and umbilical vein serum with an active GLP-1 ELISA

Fruits and vegetables checklist

Fabricatore, A